These findings suggest that the DPP IV/GLP-1 system is involved in TAC-induced diabetes mellitus and that the preservation of endogenously secreted GLP-1 by treatment with a DPP IV inhibitor is a reasonable approach in the treatment of TAC-induced diabetes. This evidence concerns the gene GCG and diabetes mellitus.